These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 32678190)
1. Early urinary protein changes during tumor formation in a NuTu-19 tail vein injection rat model. Wei J; Ni N; Meng W; Huan Y; Gao Y Sci Rep; 2020 Jul; 10(1):11709. PubMed ID: 32678190 [TBL] [Abstract][Full Text] [Related]
2. Early urine proteome changes in the Walker-256 tail-vein injection rat model. Wei J; Ni N; Meng W; Gao Y Sci Rep; 2019 Sep; 9(1):13804. PubMed ID: 31551472 [TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of urine proteome in a Walker 256 tumor-bearing rat model. Wu J; Guo Z; Gao Y Cancer Med; 2017 Nov; 6(11):2713-2722. PubMed ID: 28980450 [TBL] [Abstract][Full Text] [Related]
4. Differential urine proteome analysis of a ventilator-induced lung injury rat model by label-free quantitative and parallel reaction monitoring proteomics. Qin W; Zhang X; Chen L; Li Q; Zhang B; Sun L; Han W Sci Rep; 2021 Nov; 11(1):21446. PubMed ID: 34728735 [TBL] [Abstract][Full Text] [Related]
5. Targeted blockade of TGF-β and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Shi J; Feng J; Xie J; Mei Z; Shi T; Wang S; Du Y; Yang G; Wu Y; Cheng X; Li S; Zhu L; Yang CS; Tu S; Jie Z Sci Rep; 2017 Aug; 7(1):8660. PubMed ID: 28819126 [TBL] [Abstract][Full Text] [Related]
6. Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model. Zhang L; Li Y; Meng W; Ni Y; Gao Y Cancer Med; 2019 Jul; 8(7):3553-3565. PubMed ID: 31090175 [TBL] [Abstract][Full Text] [Related]
7. Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other Tumors. Zhang C; Leng W; Sun C; Lu T; Chen Z; Men X; Wang Y; Wang G; Zhen B; Qin J EBioMedicine; 2018 Apr; 30():120-128. PubMed ID: 29576497 [TBL] [Abstract][Full Text] [Related]
8. Deciphering key regulators involved in epilepsy-induced cardiac damage through whole transcriptome and proteome analysis in a rat model. Sharma S; Sharma M; Rana AK; Joshi R; Swarnkar MK; Acharya V; Singh D Epilepsia; 2021 Feb; 62(2):504-516. PubMed ID: 33341939 [TBL] [Abstract][Full Text] [Related]
9. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics. Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041 [TBL] [Abstract][Full Text] [Related]
10. JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Liu RY; Zeng Y; Lei Z; Wang L; Yang H; Liu Z; Zhao J; Zhang HT Int J Oncol; 2014 May; 44(5):1643-51. PubMed ID: 24573038 [TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling in ovarian cancer. Kim G; Minig L; Kohn EC Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909 [TBL] [Abstract][Full Text] [Related]
12. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566 [TBL] [Abstract][Full Text] [Related]
13. Identification of urine protein biomarkers with the potential for early detection of lung cancer. Zhang H; Cao J; Li L; Liu Y; Zhao H; Li N; Li B; Zhang A; Huang H; Chen S; Dong M; Yu L; Zhang J; Chen L Sci Rep; 2015 Jul; 5():11805. PubMed ID: 26133466 [TBL] [Abstract][Full Text] [Related]
14. [Study of the therapeutic effects of costimulatory molecules B7-1 and interleukin 12 modified tumor cells vaccines on ovarian epithelial carcinoma through induction of anti-cancer immunity of the body]. Liang HM; Jiang J; Kong BH; Ma DX; Jiang S Zhonghua Fu Chan Ke Za Zhi; 2003 Jun; 38(6):354-8. PubMed ID: 12895379 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Stakleff KS; Sloan T; Blanco D; Marcanthony S; Booth TD; Bishayee A Asian Pac J Cancer Prev; 2012; 13(4):1333-40. PubMed ID: 22799328 [TBL] [Abstract][Full Text] [Related]
16. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856 [TBL] [Abstract][Full Text] [Related]
17. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873 [TBL] [Abstract][Full Text] [Related]
18. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique. Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854 [TBL] [Abstract][Full Text] [Related]
19. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. Tang HY; Beer LA; Chang-Wong T; Hammond R; Gimotty P; Coukos G; Speicher DW J Proteome Res; 2012 Feb; 11(2):678-91. PubMed ID: 22032327 [TBL] [Abstract][Full Text] [Related]
20. Exploration of the platelet proteome in patients with early-stage cancer. Sabrkhany S; Kuijpers MJE; Knol JC; Olde Damink SWM; Dingemans AC; Verheul HM; Piersma SR; Pham TV; Griffioen AW; Oude Egbrink MGA; Jimenez CR J Proteomics; 2018 Apr; 177():65-74. PubMed ID: 29432918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]